- Home
- ATER vs NLSP Comparison
ATER vs NLSP Comparison
Compare ATER & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATER
- NLSP
- Stock Information
- Founded
- ATER 2014
- NLSP 2015
- Country
- ATER United States
- NLSP Switzerland
- Employees
- ATER N/A
- NLSP N/A
- Industry
- ATER Home Furnishings
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- ATER Consumer Discretionary
- NLSP Health Care
- Exchange
- ATER Nasdaq
- NLSP Nasdaq
- Market Cap
- ATER 15.5M
- NLSP 12.4M
- IPO Year
- ATER N/A
- NLSP 2021
- Fundamental
- Price
- ATER $1.36
- NLSP $2.20
- Analyst Decision
- ATER
- NLSP
- Analyst Count
- ATER 0
- NLSP 0
- Target Price
- ATER N/A
- NLSP N/A
- AVG Volume (30 Days)
- ATER 251.1K
- NLSP 265.8K
- Earning Date
- ATER 08-07-2025
- NLSP 07-22-2025
- Dividend Yield
- ATER N/A
- NLSP N/A
- EPS Growth
- ATER N/A
- NLSP N/A
- EPS
- ATER N/A
- NLSP N/A
- Revenue
- ATER $94,191,000.00
- NLSP N/A
- Revenue This Year
- ATER N/A
- NLSP N/A
- Revenue Next Year
- ATER $7.48
- NLSP N/A
- P/E Ratio
- ATER N/A
- NLSP N/A
- Revenue Growth
- ATER N/A
- NLSP N/A
- 52 Week Low
- ATER $1.22
- NLSP $1.30
- 52 Week High
- ATER $3.84
- NLSP $15.59
- Technical
- Relative Strength Index (RSI)
- ATER 39.29
- NLSP 43.99
- Support Level
- ATER $1.46
- NLSP $2.06
- Resistance Level
- ATER $1.56
- NLSP $2.33
- Average True Range (ATR)
- ATER 0.11
- NLSP 0.25
- MACD
- ATER -0.01
- NLSP -0.07
- Stochastic Oscillator
- ATER 4.21
- NLSP 7.84
About ATER Aterian Inc.
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products and, consumer electronics. It has various owned and operates brands, including HomeLabs, Squatty Potty, Healing Solutions, PurSteam, and others. The company generates revenue through the online sales of various consumer products that are sold online.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.